Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat on October 13, 2021, at 3:30 p.m. ET during the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference. A live webcast of the presentation can be accessed on Enanta’s website, with replays available for 30 days post-event. Enanta focuses on small molecule drug discovery for viral infections and liver diseases, including candidates for respiratory syncytial virus, hepatitis B virus, and COVID-19.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, October 13, 2021, at 3:30 p.m. ET at the H.C. Wainwright 2^nd Annual Hepatitis B Virus Virtual Conference.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for at least 30 days.

About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005361/en/

Media and Investors

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What is the date of the H.C. Wainwright Hepatitis B Virus Conference featuring Enanta Pharmaceuticals?

The conference will take place on October 13, 2021.

Who will represent Enanta Pharmaceuticals at the conference?

CEO Jay R. Luly, Ph.D. will participate in the event.

How can I access the webcast for Enanta's presentation?

The webcast can be accessed via the 'Events and Presentations' section on Enanta’s website.

What therapeutic areas does Enanta Pharmaceuticals focus on?

Enanta focuses on small molecule drugs for viral infections and liver diseases.

What candidates is Enanta developing?

Enanta is developing candidates for respiratory syncytial virus, hepatitis B virus, and COVID-19.